A study published in Nature Cancer details how OCRA-funded research has dramatically expanded the impact of DNA and RNA data in the Cancer Genome Atlas and Cancer Cell Line Encyclopedia, by analyzing samples for protein expression related to cancer. The research team behind the study includes Dr. Gordon Mills, an Ovarian Cancer Research Alliance grantee … Continued
OCRA’s 2024 Mentored Investigator Grants are supporting fresh perspectives and approaches to end ovarian and related gynecologic cancers. This year’s grants are awarded to 5 exceptional young researchers who are conducting promising studies under the mentorship of leaders in the gynecologic cancer field. “OCRA’s Mentored Investigators exemplify the innovative spirit and dedication needed to make … Continued
OCRA’s 2024 Early Career Investigator Grants are awarded to 8 outstanding young researchers with a strong commitment to ending ovarian and related gynecologic cancers. These grants fund innovative projects, and support the next generation of scientists dedicated to curing ovarian cancer. “By supporting these early career investigators, we’re fostering innovative approaches and fresh perspectives into … Continued
OCRA’s Health Equity Research Grants for 2024 are dedicated to advancing equity in care of ovarian and related gynecologic cancers, addressing deep disparities in early diagnosis, access to care, and patient outcomes. “In a year of remarkable new research being undertaken by OCRA-funded scientists, our expanded focus on health equity is more critical than ever,” … Continued
Research breakthroughs are around the corner. In 2023, OCRA announced $9.2 million in research initiatives for 2024 — the largest in our history — including awarding 20 grants to scientists at 15 prestigious institutions. Recommended for funding by OCRA’s Scientific Advisory Committee from a competitive evaluation process, these exceptional researchers and their forward-thinking studies will tackle … Continued
An OCRA research team is using Artificial Intelligence (AI) to develop a blood test to potentially detect ovarian cancer, as part of an OCRA-funded study in partnership with Microsoft AI for Good Lab. OCRA grantee Daniel Heller, PhD, lead researcher at The Daniel Heller Lab at Memorial Sloan Kettering Cancer Center discusses this cutting-edge technology … Continued
Snap Summary: OCRA-funded researchers discovered a potential key to reducing chemotherapy resistance, and reducing recurrence rates for the most common type of ovarian cancer. A research team at Magee-Women’s Research Institute, University of Pittsburgh, made a breakthrough in the fight to tackle chemoresistance, a pervasive issue in ovarian cancer treatment. This groundbreaking study was led … Continued
Snap Summary: New findings could help develop better immune therapy for patients with the most common and lethal subtype of ovarian cancer. A recent study co-authored by Dr. Sherry Wu of The University of Queensland, Brisbane, and made possible in part by funding from OCRA, is making inroads toward immunotherapy as a viable option for … Continued
Snap Summary: Research co-funded by OCRA found that foregoing genetic counseling before and after genetic testing does not negatively impact individuals who do not have a pathogenic mutation. Studies have shown that people who might have a hereditary cancer risk often do not get tested. This makes it important to identify needless barriers that may … Continued
Snap Summary: An OCRA-funded study sought to understand why certain ovarian cancer cells resist olaparib treatment, and discovered that introducing a second drug (mifepristone) while targeting certain cells (polyploid giant cancer cells) may offer a solution. In a study published in the journal Science Advances, researchers at MD Anderson Cancer Center set their sights on … Continued
Snap summary: OCRA-funded researchers set out to improve immune response against a known therapeutic target, and provided a glimpse into a world where an ovarian cancer patient’s own immune system can be harnessed to treat and eradicate the disease. Researchers at Roswell Park Comprehensive Cancer Center have made significant gains toward immunotherapy as a viable … Continued
A new study, published in the Journal of Clinical Investigation and funded in part by OCRA, has found that mesothelial cells are a critical factor in ovarian cancer metastasis. High-grade serous ovarian cancer, the most common ovarian cancer subtype, is known to be aggressive, and is associated with the presence of ascites and widespread metastases … Continued
Get email updates about research news, action alerts, and ways to join the fight.
